LINC01468 acts as a crucial driver of NAFLD-HCC progression and chemoresistance, highlighting the value of the LINC01468-SHIP2 axis as a potential therapeutic target for HCC. The gene discussed is INPPL1; the disease is metabolic dysfunction-associated steatotic liver disease.